<DOC>
	<DOCNO>NCT00394251</DOCNO>
	<brief_summary>The primary objective study compare safety dose-dense ABI-007 ( Abraxane ) 260 mg/m^2 Taxol 175 mg/m^2 give every 2 week follow dose-dense Adriamycin plus Cytoxan ( AC ) chemotherapy . Bevacizumab administer 10 mg/kg every 2 week throughout chemotherapy , 15 mg/kg every 3 week follow chemotherapy .</brief_summary>
	<brief_title>Study Dose-dense Adriamycin Plus Cytoxan ( AC ) Followed Either ABI-007 ( Abraxane ) Taxol With Bevacizumab Adjuvant Therapy Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>A patient eligible inclusion study follow criterion meet : 1 . Female , age great equal 18 less equal 70 year old . 2 . Estrogen receptor ( ER ) progesterone receptor ( PR ) status determine . 3 . Operable , histologically confirm adenocarcinoma breast 4 . Must meet 1 follow criterion : T13 , N13 , M0 , regardless ER PR status . T &gt; 2 cm , N0 , M0 ( T23N0M0 ) , regardless ER PR status . T &gt; 1 cm , N0 , M0 ( T1cN0M0 ) ER PR negative T &gt; 1 cm , N0 , M0 , ER PR positive grade 3 5 . Patients one sentinel lymph node metastasis 0.22 mm size require undergo completion axillary dissection unless 1 sentinel lymph node examine . This completion axillary dissection optional 1 2 sentinel lymph node positive micrometastasis . Therefore 1 1 sentinel lymph node positive micrometastasis ( 0.22 mm ) , completion axillary dissection require . 6 . Patients one sentinel node micrometastasis 1 node micrometastasis &gt; 2 mm and/or T3 disease must undergo completion , standard axillary dissection . Note : follow eligible T1b , c , N0M0 ER PR positive grade 1 2 Tx tumor ( regardless nodal status ) T4 disease [ i.e. , patient fix tumor , peau d'orange skin change , skin ulceration , inflammatory change Note : Sentinel lymph node micrometastasis &lt; 0.2 mm consider N0 disease 7 . Negative surgical margin lumpectomy mastectomy specimen ( ink invasive cancer ink ductal carcinoma situ [ DCIS ] ) . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 9 . Normal electrocardiogram ( ECG , assess investigator ) . 10 . No preexist peripheral neuropathy . 11 . It longer 84 day since date definitive surgery ( eg , mastectomy case breastsparing procedure , axillary dissection ) . 12 . Laboratory value follow : White blood cell count : &gt; equal 3,000/mm^3 Absolute neutrophil count : &gt; equal 1,500/mm^3 Platelets : &gt; equal 100,000/mm^3 Hemoglobin : &gt; equal 8g/dL Bilirubin : &lt; equal institution 's ULN Creatinine : &lt; equal 1.7 mg/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) alkaline phosphatase could 2.5 time institutional ULN . 13 . All stag study include physical exam , chest xray , bone scan show evidence metastatic disease , include suspicious lymphadenopathy skin nodule physical exam . A chest xray bone scan mandatory ; however , stag study treat physician 's discretion . Any staging test ( eg , Computed Tomography [ CT ] scan , magnetic resonance image [ MRI ] study , ultrasound abdomen , Positron Emission Tomography [ PET ] scan must negative metastatic disease . An abdominal CT scan PET scan mandatory patient liver function test elevate upper limit normal ( ULN ) rule metastatic disease . If patient stag PET scan bone scan necessary , chest xray require . 14 . Patient negative serum pregnancy test &lt; equal 14 day first dose study drug ( patient childbearing potential ) . 15 . If fertile , patient agree u acceptable method birth control avoid pregnancy [ Note : oral contraceptive allow ] duration chemotherapy hormonal therapy 6 month thereafter . 16 . If obese , patient must treat dos calculate use his/her actual body surface area ( BSA ) ( physician must comfortable treat full BSA dose regardless BSA ) . 17 . Patient sign Patient Informed Consent Form . A patient eligible inclusion study follow criterion apply : 1 . Patients HER2 positive breast cancer ( IHC 3+ FISH + ) eligible adjuvant Herceptin therapy . 2 . Stage IV breast cancer ( M1 disease TNM stag system ) . 3 . Prior anthracycline , anthracenedione ( mitoxantrone ) , taxane therapy 4 . Neoadjuvant therapy breast cancer . 5 . Previous invasive cancer treat &lt; 5 year prior enter study , except basal squamous cell carcinoma skin carcinoma situ cervix ; latter require occur 5 year prior study entry . 6 . Prior invasive breast cancer diagnose &lt; 5 year prior enter study . Patients must finish adjuvant hormonal therapy prior registration . Patients prior DCIS eligible . Patients DCIS treat tamoxifen must finish tamoxifen prior registration . 7 . Serious medical illness , treat study , would limit survival &lt; 4 year , psychiatric condition would prevent informed consent compliance study treatment . 8 . Uncontrolled severe cardiovascular disease include recent ( &lt; equal 12 month ) myocardial infarction unstable angina . 9 . Active uncontrolled bacterial , viral ( include clinically define Acquired Immune Deficiency Syndrome [ AIDS ] ) , fungal infection . 10 . Patients active chronic hepatitis abnormal liver function test ( LFTs ) patient know HIV positive . 11 . Uncontrolled disease uncontrolled diabetes . 12 . Any prior history hypertensive crisis hypertensive encephalopathy . 13 . Any known central nervous system ( CNS ) disease . 14 . Known hypersensitivity component bevacizumab . 15 . No history cerebrovascular accident transient ischemic attack time . 16 . Active symptomatic vascular disease , e.g. , aortic aneurysm aortic dissection , peripheral vascular disease , e.g. , claudication , within six month study entry . 17 . No major surgical procedure , open biopsy , significant traumatic injury within 28 day core biopsy minor surgical procedure ( exclude placement vascular access device ) within seven day study entry . No anticipated need major surgical procedure course study . 18 . No history abdominal fistula , gastrointestinal perforation , intra abdominal process within six month study entry . 19 . No serious nonhealing wound , ulcer , bone fracture . 20 . No proteinuria screen demonstrated urine protein : urine creatinine ( UPC ) ratio &gt; equal 1.0 urine dipstick proteinuria &gt; equal 2+ ( patient discover &gt; equal 2+ proteinuria dipstick urinalysis baseline undergone 24 hour urine collection must demonstrate &lt; equal 1g protein 24 hour eligible ) . 21 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg /or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) New York Heart Association ( NYHA ) Grade 2 great congestive heart failure . 22 . History coagulopathy , bleed diathesis , therapeutic anticoagulation low dose chronic acetyl salicylic acid ( ASA ) &gt; equal 325 mg. per day . Low dose coumadin anticoagulation venous access device low dose molecular weight heparin ( LMWH ) deep vein thrombosis prophylaxis low dose ( 325 mg less ) ASA prophylaxis allow , best avoid treat physician feel safe . 23 . Left Ventricular Ejection Fraction ( LVEF ) cardiac echocardiography ( ECHO ) &lt; 50 % ( institutional low limit normal [ LLN ] ) &gt; equal 74 % . LVEF great 75 % baseline review and/or test repeat could falsely elevate . 24 . Patients receive concurrent immunotherapy . 25 . A history malignancy within last 5 year , could affect diagnosis assessment breast cancer recurrence could shorten patient 's survival . 26 . Patient organ allograft . 27 . Patient pregnant breastfeeding . 28 . Patient unable comply requirement study . 29 . Patient receive investigational drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Adjuvant therapy</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Early stage breast cancer</keyword>
</DOC>